

18 ABSTRACT

19 Fungal pathogens are a global threat to human health. For example, fungi from the genus
20 *Aspergillus* cause a spectrum of diseases collectively known as aspergillosis. Most of the
21 >200,000 life-threatening aspergillosis infections per year worldwide are caused by
22 *Aspergillus fumigatus*. Recently, molecular typing techniques have revealed that
23 aspergillosis can also be caused by organisms that are phenotypically similar to *A.*
24 *fumigatus* but genetically distinct, such as *Aspergillus lentulus* and *Aspergillus*
25 *fumigatiaffinis*. Importantly, some of these so-called cryptic species exhibit different
26 virulence and drug susceptibility profiles than *A. fumigatus*, however, our understanding
27 of their biology and pathogenic potential has been stymied by the lack of genome
28 sequences and phenotypic profiling. To fill this gap, we phenotypically characterized the
29 virulence and drug susceptibility of 15 clinical strains of *A. fumigatus*, *A. lentulus*, and *A.*
30 *fumigatiaffinis* from Spain and sequenced their genomes. We found heterogeneity in
31 virulence and drug susceptibility across species and strains. Genes known to influence
32 drug susceptibility (*cyp51A* and *fks1*) vary in paralog number and sequence among these
33 species and strains and correlate with differences in drug susceptibility. Similarly, genes
34 known to be important for virulence in *A. fumigatus* showed variability in number of
35 paralogs across strains and across species. Characterization of the genomic similarities
36 and differences of clinical strains of *A. lentulus*, *A. fumigatiaffinis*, and *A. fumigatus* that
37 vary in disease-relevant traits will advance our understanding of the variance in
38 pathogenicity between *Aspergillus* species and strains that are collectively responsible
39 for the vast majority of aspergillosis infections in humans.

40 INTRODUCTION

41 Aspergillosis is a major health problem, with rapidly evolving epidemiology and new
42 groups of at-risk patients (Patterson et al., 2016). Aspergillosis infections are usually
43 caused by inhalation of airborne asexual spores (conidia) of *Aspergillus fumigatus* and a
44 few other *Aspergillus* species (Rokas et al., 2020). Aspergillosis covers a spectrum of
45 diseases (Latgé and Chamilos, 2020). For example, non-invasive diseases caused by
46 *Aspergillus*, such as aspergilloma, are currently classified as chronic pulmonary
47 aspergillosis and are commonly associated to pulmonary tuberculosis (Denning et al.,
48 2016). In atopic patients, the most severe form of aspergillosis is allergic
49 bronchopulmonary aspergillosis (ABPA), which develops following sensitization to *A.*
50 *fumigatus* allergens in atopic patients with cystic fibrosis or individuals with genetic
51 predisposition to ABPA (Agarwal et al., 2013). However, the most common invasive type
52 of infection is invasive pulmonary aspergillosis (IPA), whose risk is significantly increased
53 in immunocompromised individuals, in patients with acute leukaemia and recipients of
54 hematopoietic stem cells transplantation, or in solid-organ transplant recipients (Brown et
55 al., 2012). Importantly, IPA has recently been described in new groups of traditionally low-
56 risk patients, such as patients in intensive care units recovering from bacterial sepsis
57 (Latgé and Chamilos, 2020).

58

59 Although *A. fumigatus* is the major etiologic agent of aspergillosis, a few other *Aspergillus*
60 species, such as *Aspergillus flavus*, *Aspergillus terreus*, *Aspergillus niger*, and *Aspergillus*
61 *nidulans*, can also cause infections (Zakaria et al., 2020). While most of these pathogens
62 can be phenotypically easily distinguished, infections can also be caused by *Aspergillus*

63 species that are morphologically very similar to *A. fumigatus* (Rokas et al., 2020). These
64 close pathogenic relatives of *A. fumigatus* are considered sibling species or cryptic
65 species because they are undistinguishable from each other and from *A. fumigatus* by
66 classical identification methods (Alastruey-Izquierdo et al., 2014); these species vary
67 mostly in their colony growth, robustness of the production of conidia, conidial surface
68 markings, presence and absence of septation in phialides, and maximum growth
69 temperatures (Taylor et al., 2000; Balajee et al., 2005; Katz et al., 2005). As a result of
70 their near identical morphological characteristics, most of these cryptic species have only
71 recently been described. For example, *Aspergillus lentulus* was first described in 2005 in
72 a case of human aspergillosis (Balajee et al., 2005). Similarly, *A. fumigatiaffinis*, another
73 pathogenic species that is closely related to *A. fumigatus*, was first described in 2005
74 (Hong et al., 2005). Even though cryptic species were only discovered relatively recently,
75 understanding their genetic and phenotypic similarities and differences from the major
76 pathogen *A. fumigatus* is important for two reasons. First, their prevalence in the clinic
77 has been estimated to be between 11 and 19% (Balajee et al., 2009; Alastruey-Izquierdo
78 et al., 2014; Negri et al., 2014). Second, several of these species, including *A. lentulus*
79 and *A. fumigatiaffinis*, have been shown to differ in their drug susceptibility to
80 amphotericin B and azoles compared to *A. fumigatus* (Alastruey-Izquierdo et al., 2014).

81

82 An emerging realization in the study of fungal pathogens is the presence of phenotypic
83 heterogeneity among strains of the same species, especially with respect to virulence
84 and antifungal drug susceptibility (Keller, 2017). For example, a recent study reported
85 strong correlation between *in vitro* hypoxic growth phenotypes and virulence among *A.*

86 *fumigatus* strains (Kowalski et al., 2016). Similarly, *A. fumigatus* strains have previously
87 been show to exhibit great quantitative and qualitative heterogeneity in light response
88 (Fuller et al., 2016); in this case, heterogeneity in light response was not associated with
89 heterogeneity in virulence. Finally, Ries *et al.* found a high heterogeneity among *A.*
90 *fumigatus* strains with regard to nitrogen acquisition and metabolism during infection and
91 correlation between nitrogen catabolite repression-related protease secretion and
92 virulence (Ries et al., 2019). These studies highlight the biological and clinical relevance
93 of understanding strain heterogeneity in *Aspergillus* pathogens. However, comparisons
94 of strain heterogeneity in virulence and drug resistance profiles among clinical strains in
95 *A. fumigatus* and closely related cryptic species, such as *A. lentulus* and *A. fumigatiaffinis*,
96 are lacking.

97

98 To address this gap in the field, we phenotypically characterized and sequenced the
99 genomes of 15 clinical strains of *A. fumigatus*, *A. lentulus*, and *A. fumigatiaffinis* from
100 Spain. We found strain heterogeneity in both virulence and drug susceptibility profiles
101 within each species as well as differences between the three species. We found that
102 genes known to influence drug susceptibility, such as *cyp51A*, exhibit variation in their
103 numbers of paralogs and sequence among these species and strains. Similarly, we found
104 variability in the number of paralogs within and between species in many genes known to
105 be important for virulence in *A. fumigatus*. Characterization of the genomic similarities
106 and differences of clinical strains of *A. lentulus*, *A. fumigatiaffinis*, and *A. fumigatus* that
107 vary in disease-relevant traits will advance our understanding of the variation in

108 pathogenicity between *Aspergillus* species and strains that are collectively responsible
109 for the vast majority of aspergillosis infections in humans.

110 MATERIALS AND METHODS

111 Strains and species identification

112 To understand the degree of genomic heterogeneity among strains, we sequenced six
113 clinical strains of *A. fumigatus*, five of *A. lentulus* and four of *A. fumigatiaffinis* available in
114 the Mycology Reference Laboratory of the National Center for Microbiology (CNM) in
115 Instituto de Salud Carlos III in Spain (Supplementary Table 1). For initial species
116 identification, we sequenced the Internal Transcribed Spacer region (ITS) and beta-
117 tubulin (*benA*) gene amplicons (primer pairs in Supplementary Table 2). We downloaded
118 reference sequences for the type strains of *A. fumigatiaffinis* IBT12703 and *A. lentulus*
119 IFM54703, and of *Aspergillus clavatus* NRRL1 (section *Clavati*), which we used as the
120 outgroup. We aligned DNA sequences with MAFFT v.7.397 (Kato and Standley, 2013),
121 followed by model selection and phylogenetic inference in IQ-TREE v.1.6.7 (Nguyen et
122 al., 2015).

123

124 Characterization of virulence and antifungal susceptibility profiles

125 To understand the pathogenic potential of the 15 clinical strains, we carried out virulence
126 assays using the moth *Galleria mellonella* model of fungal disease (Fuchs et al., 2010).
127 Briefly, we obtained moth larvae by breeding adult moths that were kept for 24 hr prior to
128 infection under starvation, in the dark, and at a temperature of 37 °C. We selected only
129 larvae that were in the sixth and final stage of larval development. We harvested fresh
130 asexual spores (conidia) from each strain from yeast extract-agar-glucose (YAG) plates
131 in PBS solution and filtered through a Miracloth (Calbiochem). For each strain, we
132 counted the spores using a hemocytometer and created a 2×10^8 conidia/ml stock

133 suspension. We determined the viability of the administered inoculum by plating a serial
134 dilution of the conidia on YAG medium at 37°. We inoculated a total of 5µl (1x10⁶
135 conidia/larvae) to each larva (n=10). We used as the control a group composed of larvae
136 inoculated with 5µl of PBS. We performed inoculations via the last left proleg using a
137 Hamilton syringe (7000.5KH). After infection, we maintained the larvae in petri dishes at
138 37° C in the dark and scored them daily during ten days. We considered larvae that did
139 not move in response to touch as dead. To evaluate whether there was significant
140 heterogeneity in the virulence profiles of the different strains within each species, we
141 performed log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests in Graph Pad
142 (Supplementary Table 3).

143

144 To measure the antifungal susceptibility of the clinical strains, we applied the EUCAST
145 (European Committee for Antimicrobial Susceptibility Testing) reference method version
146 9.3.1 (Arendrup et al., 2017). For all strains, we tested their susceptibility to four antifungal
147 drug classes: a) Polyenes: Amphotericin B (AMB, Sigma-Aldrich Quimica, Madrid, Spain);
148 b) Azoles: itraconazole (ICZ, Janssen Pharmaceutica, Madrid, Spain), voriconazole
149 (VCZ, Pfizer SA, Madrid, Spain), posaconazole (PCZ, Schering-Plough Research
150 Institute, Kenilworth, NJ, USA); c) Echinocandins: caspofungin (CPF, Merck & Co. Inc,
151 Rahway, NJ, USA), micafungin (MCF, Astellas Pharma Inc., Tokyo Japan), anidulafungin
152 (AND, Pfizer SA. Madrid, Spain); and d) Allylamine: Terbinafine (TRB, Novartis, Basel,
153 Switzerland). The final concentrations tested ranged from 0.03 to 16 mg/liter for
154 amphotericin B, terbinafine, and caspofungin; from 0.015 to 8 mg/liter for itraconazole,
155 voriconazole and posaconazole; from 0.007 to 4 mg/liter for anidulafungin; and from 0.004

156 to 2 mg/liter for micafungin. *A. flavus* ATCC 204304 and *A. fumigatus* ATCC 204305 were
157 used as quality control strains in all tests performed. MICs for amphotericin B,
158 itraconazole, voriconazole, posaconazole, and terbinafine, and minimal effective
159 concentrations (MECs) for anidulafungin, caspofungin and micafungin were visually read
160 after 24 and 48 h of incubation at 35°C in a humid atmosphere. To assess the relationship
161 between antifungal susceptibility and strain/species identification, we carried out Principal
162 Component Analysis (PCA) with scaled MIC/MEC values with the R package FactoMineR
163 (Lê et al., 2008), and data visualization with the factoextra v.1.0.6 package.

164

165 [Genome sequencing](#)

166 To understand the genomic similarities and differences within and between these
167 pathogenic *Aspergillus* species and how they are associated with differences in drug
168 susceptibility and virulence profiles, we sequenced the genomes of all 15 strains. Each
169 strain was grown in glucose-yeast extract-peptone (GYEP) liquid medium (0.3% yeast
170 extract and 1% peptone; Difco, Soria Melguizo) with 2% glucose (Sigma-Aldrich, Spain)
171 for 24 h to 48 h at 30°C. After mechanical disruption of the mycelium by vortex mixing with
172 glass beads, genomic DNA of isolates was extracted using the phenol-chloroform method
173 (Holden DW, 1994). The preparation of DNA libraries was performed using the Nextera®
174 TM DNA Library PrepKit (Illumina Inc., San Diego, CA, USA) according to manufacturer's
175 guidelines. DNA quantification was carried out using the QuantiFluor® dsDNA System
176 and the QuantiFluor® ST Fluorometer (Promega, Madison, WI, USA) and its quality was
177 checked with the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA,
178 USA). Sequencing was performed in the Illumina platform NextSeq500, following the

179 manufacturer's protocols (Illumina Inc, San Diego, CA, USA). We performed an initial
180 quality analysis of the sequence reads using FastQC, v.0.11.7
181 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). We inspected sequence
182 reads for contaminants using BLAST (Altschul et al., 1990) and MEGAN5 (Huson and
183 Weber, 2013). We trimmed low quality bases (LEADING = 3; TRAILING = 3;
184 SLIDINGWINDOW: windowSize = 4 and requiredQuality = 15), removing both short
185 sequences (< 90 bp) and Nextera adaptors, with Trimmomatic v.0.38 (Bolger et al., 2014).

186

187 [Genome assembly and annotation](#)

188 We assembled the genomes of all strains with SPAdes v3.12.0 (Bankevich et al., 2012).
189 We corrected bases, fixed mis-assemblies, and filled gaps with Pilon, v.1.22 (Walker et
190 al., 2014). We assessed assembly quality using QUAST, v.4.6.3 (Gurevich et al., 2013).
191 We assessed genome assembly completeness using Benchmarking Universal Single-
192 Copy Orthologs (BUSCO) (Simão et al., 2015) and the 4,046 Eurotiomycetes BUSCO
193 gene set (genes from OrthoDB that are thought to be universally single copy). We carried
194 out gene prediction with AUGUSTUS v.3.3.1 (Stanke et al., 2004) using the gene models
195 of *A. fumigatus* as reference. We carried out functional annotation with InterProScan 5.34-
196 73.0 (Jones et al., 2014).

197

198 [Orthogroup identification](#)

199 To identify orthologs (and closely related paralogs) across strains, we performed all-vs-
200 all searches with blastp 2.7.1+ (Altschul et al., 1990) using the strains' predicted

201 proteomes. We used OrthoFinder v.2.3.3 (Emms and Kelly, 2015) to generate
202 orthogroups using pre-computed BLAST results (-og option) and a Markov Clustering
203 (MCL) inflation value of 1.5. We considered an orthogroup “species-specific” if it
204 possessed one or more protein sequences from only one species.

205

206 Identification of single nucleotide polymorphisms and insertions / deletions

207 To characterize genetic variation within and between the three pathogenic *Aspergillus*
208 species, we assessed single nucleotide polymorphisms (SNPs) and insertions / deletions
209 (indels). We used BWA-MEM v.0.7.17 (Li and Durbin, 2009) with default parameters to
210 map reads to the reference genome sequences for *A. fumigatus*, *A. lentulus* and *A.*
211 *fumigatiaffinis* (CNM-CM8686, CNM-CM7927, and CNM-CM6805, respectively). We did
212 not use type strains as reference genomes for the species under study, because they are
213 not from Spain. Duplicate reads were identified using PICARD MarkDuplicates v.2.9.2
214 (<http://broadinstitute.github.io/picard>). We indexed genomes using SAMTOOLS v.1.8 (Li
215 et al., 2009) for subsequent variant detection analyses. We used GenomeAnalysisTK
216 (GATK) v.3.6 for SNP calling with the recommended hard filtering parameters (McKenna
217 et al., 2010; Depristo et al., 2011). We used SnpEff v.4.3t (Cingolani P, Platts A, Wang le
218 L, Coon M, Nguyen T, Wang L, Land SJ, Lu X et al., 2013) to annotate and predict the
219 functional effect of SNPs and indels. We aligned protein and coding sequences for genes
220 of interest with MAFFT v.7.397 (Kato and Standley, 2013), using the –auto mode. We
221 used Jalview v.2.10.3 (Waterhouse et al., 2009) to visualize SNPs, and a Python script
222 to recover non-synonymous mutations compared to the reference, *A. fumigatus* A1163.

223 Enrichment analysis of GO terms in genes with high impact SNPs and indels for each
224 species was carried out with GOATOOLS v.0.9.9 (Klopfenstein et al., 2018).

225

226 Genetic determinants important for virulence

227 To examine whether SNPs, indels, and number of paralogs in a given orthogroup were
228 associated with virulence, we recovered 215 genes in *A. fumigatus* Af293 considered
229 genetic determinants of virulence based on their presence in PHI-base (Winnenburg,
230 2006) and in previously published studies (Abad et al., 2010; Kjærboelling et al., 2018).
231 We obtained functional annotation of these virulence-related genes from FungiDB
232 (Basenko et al., 2018).

233

234 Maximum-likelihood phylogenomics

235 To reconstruct the evolutionary history of our 15 strains and closely related *Aspergillus*
236 species, we first downloaded or assembled genomes of other strains of the three
237 pathogenic species or their closely relatives that are publicly available. Specifically, we
238 downloaded the genomes of *Aspergillus novofumigatus* IBT16806 (Kjærboelling et al.,
239 2018), *Aspergillus lentulus* IFM 54703^T (Kusuya et al., 2016), *Aspergillus fischeri*
240 NRRL181 (Fedorova et al., 2008), *Aspergillus udagawae* IFM46973 (Kusuya et al., 2015),
241 and *Aspergillus viridinutans* FRR_0576 (GenBank accession: GCA_004368095.1). To
242 ensure our analyses also captured the genetic diversity of *A. fumigatus*, we also included
243 additional *A. fumigatus* genomes that spanned the known diversity of *A. fumigatus* strains
244 (Lind et al., 2017). Specifically, we downloaded the genomes of *A. fumigatus* A1163

245 (Fedorova et al., 2008) and *A. fumigatus* Af293 (Nierman et al., 2005). Additionally, we
246 obtained the raw reads of *A. fumigatus* strains 12-750544 and F16311 (SRA accessions:
247 SRR617737 and ERR769500, respectively). To assemble these genomes, we first quality
248 trimmed the sequence reads using Trimmomatic, v0.36 (Bolger et al., 2014) using
249 parameters described elsewhere (leading:10, trailing:10, slidingwindow:4:20, and
250 minlen:50). The resulting quality-trimmed reads were then used for genome assembly
251 using SPAdes, v3.8.1 (Bankevich et al., 2012), using the ‘careful’ parameter and the ‘cov-
252 cutoff’ parameter set to ‘auto.’ Altogether, we analyzed a total of 24 genomes.

253

254 To identify single-copy orthologous genes among the 24 genomes, we implemented the
255 BUSCO, v.2.0.1 (Waterhouse et al., 2013; Simão et al., 2015) pipeline. Specifically, we
256 used the BUSCO pipeline to identify single-copy orthologous genes from genomes using
257 the Eurotiomycetes database of 4,046 orthologs from OrthoDB, v9 (Waterhouse et al.,
258 2013). Among the 4,096 orthologs, we identified 3,954 orthologs with at least 18 taxa
259 represented and aligned the protein sequence each ortholog individually using Mafft,
260 v7.294b (Kato and Standley, 2013), with the same parameters as described elsewhere
261 (Steenwyk et al., 2019). We then forced nucleotide sequences onto the protein alignment
262 with a custom Python, v3.5.2 (www.python.org), script using BioPython, v1.7 (Cock et al.,
263 2009). The resulting nucleotide alignments were trimmed using trimAl, v1.4 (Capella-
264 Gutierrez et al., 2009), with the ‘gappyout’ parameter. The trimmed alignments were then
265 concatenated into a single matrix with 7,147,728 sites. We then used the concatenated
266 data matrix as input into IQ-TREE, v1.6.11 (Nguyen et al., 2015), with the ‘nbest’
267 parameter set to 10. The best-fitting model of substitutions was automatically determined

268 using the Bayesian information criterion. The best-fitting model was a general time
269 general time-reversible model with empirical base frequencies, a discrete Gamma model
270 with 4 rate categories, and a proportion of invariable sites (GTR+I+F+G4) (Tavaré, 1986;
271 Yang, 1994; Yang, 1996; Vinet and Zhedanov, 2011). Lastly, we evaluated bipartition
272 support using 5,000 ultrafast bootstrap approximations (Hoang et al., 2018).

273

274 In order to build the phylogeny with Cyp51 paralogs, we recovered protein sequences
275 from two orthogroups that included Cyp51A and Cyp51B from *A. fumigatus* Af293
276 (Afu4g06890 and Afu7g03740, respectively). We generated a maximum-likelihood
277 phylogeny in IQ-Tree v. 1.6.12 (Nguyen et al., 2015), using 1000 Ultrafast Bootstrap
278 Approximation (UFBoot) replicates. The LG+G4 model was chosen as the best according
279 to Bayesian Information Criterion.

280

281 [Data availability](#)

282 All genomes sequenced as part of this work can be accessed through BioProject
283 PRJNA592352; the raw sequence reads are also available through the NCBI Sequence
284 Read Archive. BioSample and Assembly identifiers are presented in Supplementary
285 Table 4. Codes and scripts used in this project are available on the Gitlab repository under
286 https://gitlab.com/SantosRAC/afum_afma_alen2020.

287

288 RESULTS

289 Clinical strains show varying antifungal drug susceptibility

290 By performing PCA on the antifungal drug susceptibility values of all 15 strains, we found
291 that the strains exhibited high heterogeneity in their drug resistance profiles (Figure 1A).
292 In many cases, we found that strains from different species exhibited more similar
293 susceptibility patterns to each other (e.g., strain CNM-CM8686 from *A. fumigatus* with
294 strain CNM-CM6069 from *A. lentulus*) than to other strains from the same species (e.g.,
295 strain CNM-CM8686 with strain CNM-CM8057 from *A. fumigatus*), highlighting the
296 magnitude of heterogeneity in drug susceptibility of these species and strains. Principal
297 Component 1 (PC1) explained 37.2% of the variation and separated almost all *A.*
298 *fumigatus* strains from those of the other two species. Principal Component 2 (PC2)
299 explained 21% of the variation, but did not separate species. The individual contributions
300 of each antifungal drug to each PC are shown in Supplementary Figure 1. We identified
301 that the susceptibility of three antifungals was negatively correlated: micafungin (MCF)
302 *versus* amphotericin B (AMB) and terbinafine (TRB) *versus* AMB (Supplementary Figure
303 1). In contrast, anidulafungin (AND) and voriconazole (VCZ) were positively correlated
304 (Supplementary Figure 2).

305

306 We also looked at the differences in susceptibility between strains for each antifungal
307 drug (Figure 1B). Our data show that clinical strains of *A. fumigatus* exhibit lower MICs to
308 AMB compared to *A. lentulus* and *A. fumigati**affinis*, albeit different levels are observed
309 among different strains (one-way ANOVA; $\alpha < 0.05$; Tukey multiple comparisons of
310 means for AMB) (Table 1). With the exception of susceptibility of *A. fumigatus* and *A.*

311 *lentulus* to AMB, for which a significant difference is observed between these two species,
312 we observed high heterogeneity among strains of different species for the other drugs
313 (Table 1). Among azoles, itraconazole (ICZ) and VCZ displayed higher levels of variability
314 across strains. With respect to TRB, the four *A. fumigatiaffinis* strains exhibited low MICs,
315 whereas four *A. fumigatus* strains displayed higher MICs (MIC values >1mg/L) and the
316 other two *A. fumigatus* strains even higher; finally, one *A. lentulus* strain (CNM-CM8694)
317 displayed the highest MICs across all strains (albeit other strains showed in general lower
318 MICs). Among echinocandin drugs, caspofungin (CPF) showed high MECs for the three
319 species. In particular, one strain of *A. fumigatiaffinis* and three of *A. lentulus* were notable
320 in exhibiting very high MECs (MECs \geq 1mg/L). MECs for MCF and AND were low
321 (\leq 0.125mg/L) for all strains.

322

323 [Clinical strains show varying levels of virulence](#)

324 Given functional similarities of the greater wax moth *Galleria mellonella* innate immune
325 system with that of mammals, and prior work showing that moth larvae and mice exhibit
326 similar survival rates when infected with *A. nidulans* (Fernandes et al., 2017), we infected
327 *G. mellonella* larvae with all 15 strains (Figure 2).

328

329 Survival curves revealed high heterogeneity in virulence across clinical strains in the three
330 species (Figure 2). We observed highly virulent strains for which all ten larvae were dead
331 at day 10, such as *A. fumigatus* Af293 (one of our reference strain), *A. fumigatiaffinis*
332 CNM-CM5878 and *A. lentulus* CNM-CM8927. In contrast, other strains were less virulent

333 and >25% larvae survived to the last day of data collection, such as *A. lentulus* CNM-
334 CM6069 and CNM-CM8060. Moreover, we confirmed a high heterogeneity in virulence
335 across strains in the same or in different species (Mantel-Cox and Gehan-Breslow-
336 Wilcoxon tests are shown in the Supplementary Table 3). For example, a similar survival
337 curve is shared between *A. fumigatus* CNM-CM8812 and *A. fumigatiaffinis* CNM-
338 CM5878, whereas *A. fumigatus* CNM-CM8812 and CNM-CM8714 lead to different
339 results.

340

341 [Genomic variation within and between Spanish strains of *A. fumigatus*, *A. lentulus*, and](#) 342 [*A. fumigatiaffinis*](#)

343 To begin exploring the potential genetic underpinnings of species and strain variation in
344 drug susceptibility and virulence, we conducted comparative genomic analyses. The
345 genomes of all 15 strains were of high quality and contained 97-98% of expected
346 complete and single-copy BUSCOs (Supplementary Table 4).

347

348 *A. lentulus* and *A. fumigatiaffinis* genomes had larger gene repertoires (9,717 - 9,842 and
349 10,329 – 10,677, respectively) than *A. fumigatus* (8,837 – 8,938), consistent with previous
350 genome studies of *A. lentulus* and *A. fumigatus* (Nierman et al., 2005; Fedorova et al.,
351 2008; Kusuya et al., 2016). A genome-scale phylogenetic analysis using the nucleotide
352 sequences of BUSCOs with previously sequenced strains (Figure 3A) supports the close
353 relationship between *A. lentulus* and *A. fumigatiaffinis*.

354

355 Genome diversity among and within species across clinical strains

356 Examination of orthogroups across the fifteen strains and three species revealed that
357 most genes (7,938) are shared by all three species (Figure 3B). *A. fumigatiaffinis* has a
358 larger set of species-specific genes (1,062) than *A. lentulus* (656) or *A. fumigatus* (645),
359 consistent with its larger genome size and gene number. The numbers of shared genes
360 between *A. lentulus* and *A. fumigatiaffinis* are also higher than intersections between each
361 of them with *A. fumigatus*, consistent with their closer evolutionary affinity (Figure 3A).
362 Within each species, most orthogroups are found in all strains (9,008, 8,321, and 9,423
363 in *A. lentulus*, *A. fumigatus*, and *A. fumigatiaffinis*, respectively); approximately 5.4-6.13%
364 of genes in each species appear to vary in their presence between strains
365 (Supplementary Figure 3). Among these, we noted that orthogroups that are present all
366 but one strain are usually the most frequent (Figure 3C).

367

368 We identified a total of 114,378, 160,194, and 313,029 SNPs in *A. fumigatus*, *A.*
369 *fumigatiaffinis* and *A. lentulus*, respectively. We identified 406, 493, and 747 SNPs in *A.*
370 *fumigatus*, *A. fumigatiaffinis* and *A. lentulus*, respectively as high-impact polymorphisms;
371 these polymorphisms are those whose mutation is presumed to be highly deleterious to
372 protein function). Similarly, out of a total of 11,698 (*A. fumigatus*), 20,135 (*A.*
373 *fumigatiaffinis*) and 34,506 (*A. lentulus*) indels segregating within each species, we
374 identified 615, 1,739, and 1,830 high-impact indels in *A. fumigatus*, *A. fumigatiaffinis*, and
375 *A. lentulus*, respectively.

376

377 Gene Ontology (GO) enrichment analysis was carried out for genes with high impact
378 SNPs and indels ($\alpha = 0.05$). *A. fumigatus* only showed GO terms identified as
379 underrepresented in “cellular process” and several cellular compartments (“protein-
380 containing complex”, “intracellular organelle part”, “organelle part”, “cytoplasmic part”,
381 “cell part”). *A. lentulus* had “nucleoside metabolic” and “glycosyl compound metabolic
382 processes” enriched, and *A. fumigatiaffinis* showed enriched terms for “modified amino
383 acid binding”, “phosphopantetheine binding”, “amide binding”, “transition metal ion
384 binding”, “zinc ion binding”, “chitin binding”, and “ADP binding”. *A. lentulus* and *A.*
385 *fumigatiaffinis* genes with high impact SNPs and indels also showed underrepresented
386 GO terms (Supplementary Table 5). We also analysed SNPs and indels separately
387 (Supplementary Table 5).

388

389 Polymorphisms in major antifungal target genes correlate with antifungal susceptibility

390 Given the observed variation within and between species in antifungal drug susceptibility,
391 we examined DNA sequence polymorphisms in genes known to be involved in antifungal
392 susceptibility to azoles and echinocandins. In particular, we examined patterns of
393 sequence variation in the 14 α -sterol demethylase gene *cyp51A* (Afu4g06890) and in the
394 1,3-beta-glucan synthase catalytic subunit gene *fks1* (Afu6g12400). Using *A. fumigatus*
395 A1163 as reference, we identified important species- and strain-specific polymorphisms
396 in both *cyp51A* and *fks1* (Figure 4A; Table 2 shows a detailed breakdown of all SNP and
397 indel polymorphisms per strain).

398

399 An alignment of Cyp51A protein sequences in the three species shows possible insertions
400 in different sites (Figure 4A - red arrow). We observed substitutions in at least one of the
401 clinical strains in the three species in 42 positions that might be correlated with the strains'
402 varying drug susceptibility levels. For instance, Cyp51A in *A. fumigatus* CNM-CM8714
403 revealed a well-documented substitution related to azole resistance at position 98 (L98H)
404 (Figure 4A - blue arrows), which might be correlated to its lower susceptibility to ICZ or
405 VCZ compared to other *A. fumigatus* strains (Figure 1B).

406

407 We also looked at the promoter region of the *cyp51A* gene (Figure 4B) and identified the
408 Tandem Repeat (TR) insertions TR34 and TR46, previously reported in antifungal
409 resistant strains (Dudakova et al., 2017). These changes were specific to certain clinical
410 strains of *A. fumigatus*. For example, *A. fumigatus* CNM-CM8714 carries the TR34
411 insertions whereas *A. fumigatus* CNM-CM8057 has a TR46 (region highlighted between
412 blue arrows). There are other variations (short indels) that were exclusive to either *A.*
413 *lentulus* or *A. fumigatiaffinis*, or both.

414

415 Examination of the Fks1 protein sequence alignment from strains of the three species
416 also revealed substitutions in 39 sites (Figure 4A). We also observed an insertion at
417 position 1,626 of *A. lentulus* CNM-CM8927 (red arrow). Fks1 also showed substitutions
418 at positions comprising an important hot-spot 2 (HS2) (blue arrows): all *A. lentulus* strains
419 have a substitution at position 1,349 (I1349V) and all *A. fumigatiaffinis* have a substitution
420 at position 1,360 (T1360I).

421

422 Examination of orthogroups revealed that the orthogroup that includes the *cyp51A* gene
423 (Afu4g06890) contained additional paralogs of the *cyp51* family. Thus, we carried out a
424 phylogenetic analysis with the amino acid sequences with the orthogroups containing
425 *cyp51A* and *cyp51B* genes in *A. fumigatus* Af293 (Figure 4C) that comprises the three
426 species in this work. We observed three well-defined clades. The *A. fumigatiaffinis*
427 paralog related to *cyp51A* is likely to represent *cyp51C*, which has been previously
428 reported in other *Aspergillus* species (Hagiwara et al., 2016). Sequence identity between
429 the putative Cyp51C protein in *A. fumigatiaffinis* CNM-CM6805 and Cyp51C
430 (XM_002383890.1) and Cyp51A (XM_002375082.1) of *A. flavus* (Liu et al., 2012) is
431 471/512 (92%) and 391/508 (77%), respectively.

432

433 Genetic determinants involved in virulence: single-nucleotide polymorphisms, insertions
434 / deletions across strains and within species conservation

435 To explore the genetic underpinnings of the observed strain heterogeneity in virulence
436 we next examined the SNPs and indels in 215 genes that have previously been
437 characterized as genetic determinants of virulence in *A. fumigatus* (Supplementary Table
438 6).

439

440 Most virulence genetic determinants (146 genes) were found in single-copy in all strains
441 (Supplementary Table 7), whereas 57 genes varied in their number of paralogs across
442 clinical strains (Figure 5). We also identified four virulence determinants that had no

443 orthologs in either *A. lentulus* or *A. fumigatiaffinis*, such as Afu6g07120 (*nudC*), which is
444 an essential protein involved in nuclear movement (Morris et al., 1998), and considered
445 an essential gene in *A. fumigatus* (Hu et al., 2007). Interestingly, we noted 17 virulence
446 determinants that are present in *A. fumigatus* and *A. fumigatiaffinis* but absent in *A.*
447 *lentulus* (Figure 5 – top panel), such as Afu8g00200 (*ftmD*), one of the genes in the
448 fumitremorgin biosynthetic gene cluster (Abad et al., 2010).

449

450 Several virulence determinants exhibited larger numbers of paralogs in one or more
451 species. For example, the conidial pigment polyketide synthase *alb1* (Afu2g17600), which
452 is involved in conidial morphology and virulence (Tsai et al., 1998), is one of the
453 determinants with highest number of paralogs in *A. lentulus* and *A. fumigatiaffinis* (n=7)
454 when compared to *A. fumigatus* strains (n=4). For determinants that contained a gene in
455 at least one strain, we tested correlations between number of paralogs and virulence
456 (lethal time 50: day at which 50% of the larvae were dead, or “ND-end”: the number of
457 dead larvae at the end of the experiment) and we observed no significant correlation
458 suggesting paralog number does not associate with virulence.

459

460 DISCUSSION

461 *A. fumigatus* and the closely related species *A. lentulus* and *A. fumigatiaffinis* are
462 important causal agents of aspergillosis (Zbinden et al., 2012; Lamoth, 2016). Importantly,
463 the emergence of antifungal resistance is of increasing worldwide concern (Fisher et al.,
464 2018) and antifungal resistant strains of *A. lentulus*, and *A. fumigatiaffinis* (Alastruey-

465 Izquierdo et al., 2014) have been identified. Heterogeneity in virulence across different
466 strains of *A. fumigatus* has also been known for some time (Mondon et al., 1996).
467 Analyses of strain phenotypic and genetic heterogeneity allow us to identify correlations
468 between phenotype and genotype in strains of *Aspergillus* pathogens.

469

470 We found that high heterogeneity exists in drug susceptibility and virulence across
471 different strains of *A. fumigatus*, *A. lentulus*, and *A. fumigatiaffinis*. For one specific
472 antifungal drug, amphotericin B, our results confirmed previous findings that *A. fumigatus*
473 is more susceptible to AMB than strains of cryptic species (Balajee et al., 2004). Studies
474 on the intrinsic resistance to AMB reported for *A. terreus* highlight the importance of stress
475 response pathways, in particular heat shock proteins (such as Hsp90 and Hsp70), as well
476 as enzymes detoxifying reactive oxygen species (Posch et al., 2018). Future work
477 involving genomics on the cryptic species will be able to exploit changes in genetic
478 determinants involved in AMB susceptibility, although this drug is not commonly used in
479 clinical settings.

480

481 Regarding virulence, previous work (Sugui et al., 2014) compared survival curves
482 between different species of *Aspergillus* and concluded that *A. fumigatus* is significantly
483 more virulent than *A. lentulus* based on type strains. However, using the *Galleria* model
484 of fungal infection we found that observed within-species variance is greater than it would
485 be intuitively expected for different species. While additional testing using diverse models
486 of fungal disease will be required to test the validity of these observations, our findings

487 reinforce the emerging view that examining within-species variation in *Aspergillus*
488 pathogens is an important, yet poorly studied and understood, dimension of fungal
489 virulence.

490

491 The advent of whole genome sequencing boosted our understanding of the biology of the
492 genus *Aspergillus* (de Vries et al., 2017). Several works have previously analysed
493 genomic data of *A. fumigatus* strains (Abdolrasouli et al., 2015; Takahashi-Nakaguchi et
494 al., 2015), uncovering *cyp51A* mutations in *A. fumigatus* populations (Abdolrasouli et al.,
495 2015). Some studies have also focused on antifungal drug susceptibility (Garcia-Rubio et
496 al., 2018) or virulence potential (Puértolas-Balint et al., 2019) using only the genome
497 sequencing data for strains of *A. fumigatus*. Correlations between phenotypic traits, such
498 as antifungal susceptibility or virulence and genetic traits have been also studied in other
499 well-studied pathogens, such as the opportunistic yeast *Candida albicans* (Hirakawa et
500 al., 2015). However, to our knowledge, this is the first study that examines the phenotypic
501 and genetic heterogeneity among strains of species closely related to *A. fumigatus*.

502

503 The three main classes of antifungal drugs comprise polyenes, azoles, and
504 echinocandins, involved in ergosterol composition of fungal membrane, ergosterol
505 biosynthesis, and the cell wall biopolymer (1,3)- β -D-glucan, respectively (Robbins et al.,
506 2017). Due to toxicity to host cells, polyenes are only used in exceptional cases, and first-
507 line prophylaxis and treatment of aspergillosis is usually carried out with azoles (Garcia-
508 Rubio et al., 2017; Garcia-Vidal et al., 2019). In *A. fumigatus*, research has focused on

509 azole susceptibility testing and correlation with point mutations in the *cyp51A* gene and
510 tandem repeat insertions in its promoter region (Chen et al., 2020; Zakaria et al., 2020).
511 Studies on echinocandins have focused on the (1,3)- β -D-glucan synthase enzyme,
512 encoded by the *fks1* gene (Robbins et al., 2017). Particularly, two hot-spots have been
513 studied (Gonçalves et al., 2016). Although most studies report mutations in *Candida*,
514 previous work reported point mutations in *fks1* hot spot 1 associated with echinocandin
515 resistance in *A. fumigatus* (Jiménez-Ortigosa et al., 2017). This work did not find changes
516 among *A. fumigatus* clinical strains, but we did observe changes in hot spot 2 that were
517 specific to the cryptic species; further examination of these changes with respect to
518 echinocandin susceptibility is an interesting future avenue of research.

519

520 Major changes in protein Cyp51A that correlated with azole resistance include the
521 TR34/L98H and the TR46/Y121F/T289A changes (Beardsley et al., 2018). In previous
522 studies, alterations such as the insertion of TR34 and TR46 (Dudakova et al., 2017) were
523 only found in the *cyp51A* promoter of *A. fumigatus* strains. However, as Dudakova et al.
524 previously mentioned, “data on *cyp51* promoter alterations are scarce” outside *A.*
525 *fumigatus* (Dudakova et al., 2017). Our work explored the promoter region of the *cyp51A*
526 gene in *A. lentulus* and *A. fumigatiaffinis*, two closely related pathogenic species, and
527 identified these promoter region changes only in two strains of *A. fumigatus* and not in
528 either of the two cryptic species. We also identified other changes in proteins encoded by
529 *cyp51A* and *fks1* that can be used in the future to generate mutants and test the effect of
530 mutations in well-studied wild-type strains of *A. fumigatus* (Chen et al., 2020).

531

532 The evolution of the gene families that contain genes involved in drug resistance might
533 also give us clues on how drug resistance evolves in fungal populations; previous studies
534 (Hawkins et al., 2014; Zheng et al., 2019) report two paralogs of *cyp51* in *Aspergillus*
535 *fumigatus*, *Penicillium digitatum*, *Magnaporthe oryzae* and *A. nidulans*, while *Fusarium*
536 *graminearum* and *A. flavus* have three *cyp51* genes (Dudakova et al., 2017). Interestingly,
537 our study found a paralog of the *cyp51A* gene in *A. fumigatiaffinis* that likely corresponds
538 to *cyp51C*. Whole-genome sequence analysis in *A. flavus* reported substitutions in the
539 three paralogous genes (*cyp51A*, *cyp51B*, and *cyp51C*) in the context of antifungal
540 resistance (Sharma et al., 2018). Novel substitutions identified in *cyp51C* and modelling
541 of protein changes suggested possible effects on drug binding. Next steps in studies of
542 azole susceptibility in *A. fumigatiaffinis* strains could include the analysis of this putative
543 *cyp51C* gene and its role in the organism's observed drug susceptibility profile.

544

545 While we extended the understanding of strain heterogeneity to strains in the three
546 different species of *Aspergillus* pathogens in terms of virulence and drug susceptibility,
547 phylogenomic analyses support the between-species groupings (e.g. closer relationship
548 between *A. lentulus* and *A. fumigatiaffinis* than each of these species to *A. fumigatus*)
549 inferred when using single phylogenetic markers (e.g., from analyses of *benA*). While the
550 analysis of disease-relevant genes (e.g., *cyp51A* and *fks1*) and patterns of paralogous
551 gene number of the genetic determinants of virulence support the relationships depicted
552 in phylogenies, we see many strain-specific changes. Our work is a first opportunity to

553 exploit these specific variants that must be related to variance in virulence and drug
554 susceptibility (if the source is genetic variation).

555

556 Albeit this study focused on substitutions in genes *cyp51A* and *fks1*, there is also
557 increasing research on non-*cyp51* (Zakaria et al., 2020) and non-*fks1* (Szalewski et al.,
558 2018) genetic changes. Future exploitation of genomic data on strains of *A. fumigatus*
559 and closely related species could also exploit these additional genes. These future
560 studies could also exploit new antifungal drugs, such as olorofim, which has also been
561 tested on cryptic species of *Aspergillus* (Rivero-Menendez et al., 2019). Finally, future
562 phenotypic and genomic analyses can help us to better understand more complex topics
563 involving antifungal drugs, such as resistance, persistence and tolerance (as well as the
564 role of tolerance in resistance) (Berman and Krysan, 2020). Given possible emergence
565 of antifungal resistance in agriculture (Hawkins et al., 2019), future work could also exploit
566 correlations in antifungals and the origin of these isolates.

567

568 AUTHOR CONTRIBUTIONS

569 R.A.C.S., J.L.S., M.E.M., A.A.I., G.H.G., and A.R. designed the experiments. L.P., O.R.M.
570 and R.W.B. performed experiments. R.A.C.S. and J.L.S. ran bioinformatic analyses.
571 R.A.C.S., M.E.M., J.L.S. and A.R. wrote the manuscript. All authors revised the
572 manuscript.

573

574 **FUNDING**

575 R.A.C.S. holds Brazilian São Paulo Research Foundation (FAPESP) scholarships
576 17/21983-3 and 19/07526-4. J.L.S. and A.R. are supported by the Howard Hughes
577 Medical Institute through the James H. Gilliam Fellowships for Advanced Study program.
578 M.E.M. and A.R. were supported by a Vanderbilt University Discovery Grant. Research
579 in A.R.'s lab is also supported by the National Science Foundation (DEB-1442113), and
580 GHG by the Brazilian São Paulo Research Foundation (FAPESP) (grant number
581 2016/07870-9) and Conselho Nacional de Desenvolvimento Científico e Tecnológico
582 (CNPq). A.A.I is supported by research projects from the Fondo de Investigación
583 Sanitaria (PI13/02145 and PI16CIII/00035).

584

585 **ACKNOWLEDGEMENTS**

586 This work used resources of the "Centro Nacional de Processamento de Alto
587 Desempenho em São Paulo (CENAPAD-SP). Computational infrastructure was provided
588 by The Advanced Computing Center for Research and Education (ACCRE) at Vanderbilt
589 University.

590

591 **REFERENCES**

592 Abad, A., Victoria Fernández-Molina, J., Bikandi, J., Ramírez, A., Margareto, J., Sendino,
593 J., et al. (2010). What makes *Aspergillus fumigatus* a successful pathogen? Genes
594 and molecules involved in invasive aspergillosis. *Rev. Iberoam. Micol.*
595 doi:10.1016/j.riam.2010.10.003.

- 596 Abdolrasouli, A., Rhodes, J., Beale, M. A., Hagen, F., Rogers, T. R., Chowdhary, A., et
597 al. (2015). Genomic context of azole resistance mutations in *Aspergillus fumigatus*
598 determined using whole-genome sequencing. *MBio*. doi:10.1128/mBio.00536-15.
- 599 Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., et al. (2013).
600 Allergic bronchopulmonary aspergillosis: Review of literature and proposal of new
601 diagnostic and classification criteria. *Clin. Exp. Allergy*. doi:10.1111/cea.12141.
- 602 Alastruey-Izquierdo, A., Alcazar-Fuoli, L., and Cuenca-Estrella, M. (2014). Antifungal
603 susceptibility profile of cryptic species of *aspergillus*. *Mycopathologia*.
604 doi:10.1007/s11046-014-9775-z.
- 605 Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local
606 alignment search tool. *J. Mol. Biol.* doi:10.1016/S0022-2836(05)80360-2.
- 607 Arendrup MC, Meletiadis J, Mouton JW, Lagrou K, Howard SJ, Subcommittee on
608 Antifungal Susceptibility Testing of the ESCMID European Committee for
609 Antimicrobial Susceptibility Testing. 2017. EUCAST DEFINITIVE DOCUMENT
610 E.DEF 9.3.1: Method for the determination of broth dilution minimum inhibitory
611 concentrations of antifungal agents for conidia forming moulds.
612 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAS
613 [T E Def 9 3 1 Mould testing definitive.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAS_T_E_Def_9_3_1_Mould_testing_definitive.pdf)
- 614 Balajee, S. A., Gribskov, J. L., Hanley, E., Nickle, D., and Marr, K. A. (2005). *Aspergillus*
615 *lentulus* sp. nov., a new sibling species of *A. fumigatus*. *Eukaryot. Cell*.
616 doi:10.1128/EC.4.3.625-632.2005.

- 617 Balajee, S. A., Kano, R., Baddley, J. W., Moser, S. A., Marr, K. A., Alexander, B. D., et al.
618 (2009). Molecular identification of *Aspergillus* species collected for the transplant-
619 associated infection surveillance network. *J. Clin. Microbiol.*
620 doi:10.1128/JCM.01070-09.
- 621 Balajee, S. A., Weaver, M., Imhof, A., Gribskov, J., and Marr, K. A. (2004). *Aspergillus*
622 *fumigatus* Variant with Decreased Susceptibility to Multiple Antifungals. *Antimicrob.*
623 *Agents Chemother.* doi:10.1128/AAC.48.4.1197-1203.2004.
- 624 Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., et al.
625 (2012). SPAdes: A new genome assembly algorithm and its applications to single-
626 cell sequencing. *J. Comput. Biol.* doi:10.1089/cmb.2012.0021.
- 627 Basenko, E. Y., Pulman, J. A., Shanmugasundram, A., Harb, O. S., Crouch, K., Starns,
628 D., et al. (2018). FungiDB: An integrated bioinformatic resource for fungi and
629 oomycetes. *J. Fungi.* doi:10.3390/jof4010039.
- 630 Beardsley, J., Halliday, C. L., Chen, S. C. A., and Sorrell, T. C. (2018). Responding to the
631 emergence of antifungal drug resistance: Perspectives from the bench and the
632 bedside. *Future Microbiol.* doi:10.2217/fmb-2018-0059.
- 633 Berman, J., and Krysan, D. J. (2020). Drug resistance and tolerance in fungi. *Nat. Rev.*
634 *Microbiol.* doi:10.1038/s41579-019-0322-2.
- 635 Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: A flexible trimmer for
636 Illumina sequence data. *Bioinformatics.* doi:10.1093/bioinformatics/btu170.

- 637 Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., and White, T.
638 C. (2012). Hidden killers: Human fungal infections. *Sci. Transl. Med.*
639 doi:10.1126/scitranslmed.3004404.
- 640 Capella-Gutierrez, S., Silla-Martinez, J. M. & Gabaldon, T. trimAl: a tool for automated
641 alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* 25, 1972–
642 1973 (2009).
- 643 Chen, P., Liu, M., Zeng, Q., Zhang, Z., Liu, W., Sang, H., et al. (2020). Uncovering New
644 Mutations Conferring Azole Resistance in the *Aspergillus fumigatus* cyp51A Gene.
645 *Front. Microbiol.* doi:10.3389/fmicb.2019.03127.
- 646 Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, R. D.,
647 Cingolani, P., Platts, A., Wang, L. L. L., Coon, M., Nguyen, T., et al. (2013). A
648 program for annotating and predicting the effects of single nucleotide polymorphisms,
649 SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118 ; iso-2; iso-3.
650 *Fly (Austin)*. doi:10.1016/S1877-1203(13)70353-7.
- 651 Cock, P. J. A. *et al.* Biopython: freely available Python tools for computational molecular
652 biology and bioinformatics. *Bioinformatics* 25, 1422–1423 (2009)
- 653 de Vries, R. P., Riley, R., Wiebenga, A., Aguilar-Osorio, G., Amillis, S., Uchima, C. A., et
654 al. (2017). Comparative genomics reveals high biological diversity and specific
655 adaptations in the industrially and medically important fungal genus *Aspergillus*.
656 *Genome Biol.* doi:10.1186/s13059-017-1151-0.

- 657 Denning, D. W., Cadranel, J., Beigelman-Aubry, C., Ader, F., Chakrabarti, A., Blot, S., et
658 al. (2016). Chronic pulmonary aspergillosis: Rationale and clinical guidelines for
659 diagnosis and management. *Eur. Respir. J.* doi:10.1183/13993003.00583-2015.
- 660 Depristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., et al.
661 (2011). A framework for variation discovery and genotyping using next-generation
662 DNA sequencing data. *Nat. Genet.* doi:10.1038/ng.806.
- 663 Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig,
664 M., et al. (2017). Molecular tools for the detection and deduction of azole antifungal
665 drug resistance phenotypes in *Aspergillus* species. *Clin. Microbiol. Rev.*
666 doi:10.1128/CMR.00095-16.
- 667 Emms, D. M., and Kelly, S. (2015). OrthoFinder: solving fundamental biases in whole
668 genome comparisons dramatically improves orthogroup inference accuracy.
669 *Genome Biol.* doi:10.1186/s13059-015-0721-2.
- 670 Fedorova, N. D., Khaldi, N., Joardar, V. S., Maiti, R., Amedeo, P., Anderson, M. J., et al.
671 (2008). Genomic islands in the pathogenic filamentous fungus *Aspergillus fumigatus*.
672 *PLoS Genet.* doi:10.1371/journal.pgen.1000046.
- 673 Fernandes, C., Fonseca, F., Goldman, G., Pereira, M., and Kurtenbach, E. (2017). A
674 Reliable Assay to Evaluate the Virulence of *Aspergillus nidulans* Using the
675 Alternative Animal Model *Galleria mellonella* (Lepidoptera). *BIO-PROTOCOL.*
676 doi:10.21769/bioprotoc.2329.

- 677 Fisher, M. C., Hawkins, N. J., Sanglard, D., and Gurr, S. J. (2018). Worldwide emergence
678 of resistance to antifungal drugs challenges human health and food security. *Science*
679 (80-). doi:10.1126/science.aap7999.
- 680 Fuchs, B. B., O'Brien, E., Houry, J. B. E., and Mylonakis, E. (2010). Methods for using
681 *Galleria mellonella* as a model host to study fungal pathogenesis. *Virulence*.
682 doi:10.4161/viru.1.6.12985.
- 683 Fuller, K. K., Cramer, R. A., Zegans, M. E., Dunlap, J. C., and Loros, J. J. (2016).
684 *Aspergillus fumigatus* photobiology illuminates the marked heterogeneity between
685 isolates. *MBio*. doi:10.1128/mBio.01517-16.
- 686 Garcia-Rubio, R., Alcazar-Fuoli, L., Monteiro, M. C., Monzon, S., Cuesta, I., Pelaez, T.,
687 et al. (2018). Insight into the significance of *aspergillus fumigatus* cyp51A
688 polymorphisms. *Antimicrob. Agents Chemother*. doi:10.1128/AAC.00241-18.
- 689 Garcia-Rubio, R., Cuenca-Estrella, M., and Mellado, E. (2017). Triazole Resistance in
690 *Aspergillus* Species: An Emerging Problem. *Drugs*. doi:10.1007/s40265-017-0714-
691 4.
- 692 Garcia-Vidal, C., Alastruey-Izquierdo, A., Aguilar-Guisado, M., Carratalà, J., Castro, C.,
693 Fernández-Ruiz, M., et al. (2019). Executive summary of clinical practice guideline
694 for the management of invasive diseases caused by *Aspergillus*: 2018 Update by the
695 GEMICOMED-SEIMC/REIPI. *Enferm. Infec. Microbiol. Clin*.
696 doi:10.1016/j.eimc.2018.03.018.

- 697 Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., and Colombo, A. L. (2016).
698 Epidemiology and molecular mechanisms of antifungal resistance in *Candida* and
699 *Aspergillus*. *Mycoses*. doi:10.1111/myc.12469.
- 700 Gurevich, A., Saveliev, V., Vyahhi, N., and Tesler, G. (2013). QAST: Quality
701 assessment tool for genome assemblies. *Bioinformatics*.
702 doi:10.1093/bioinformatics/btt086.
- 703 Hagiwara, D., Watanabe, A., Kamei, K., and Goldman, G. H. (2016). Epidemiological and
704 genomic landscape of azole resistance mechanisms in *Aspergillus* fungi. *Front.*
705 *Microbiol.* doi:10.3389/fmicb.2016.01382.
- 706 Hawkins, N. J., Bass, C., Dixon, A., and Neve, P. (2019). The evolutionary origins of
707 pesticide resistance. *Biol. Rev.* doi:10.1111/brv.12440.
- 708 Hawkins, N. J., Cools, H. J., Sierotzki, H., Shaw, M. W., Knogge, W., Kelly, S. L., et al.
709 (2014). Paralog re-emergence: A novel, historically contingent mechanism in the
710 evolution of antimicrobial resistance. *Mol. Biol. Evol.* doi:10.1093/molbev/msu134.
- 711 Hirakawa, M. P., Martinez, D. A., Sakthikumar, S., Anderson, M. Z., Berlin, A., Gujja, S.,
712 et al. (2015). Genetic and phenotypic intra-species variation in *Candida albicans*.
713 *Genome Res.* doi:10.1101/gr.174623.114.
- 714 Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. & Vinh, L. S. UFBoot2:
715 Improving the Ultrafast Bootstrap Approximation. *Mol. Biol. Evol.* **35**, 518–522
716 (2018).

- 717 Holden DW. (1994) DNA mini prep method for *Aspergillus fumigatus* (and other
718 filamentous fungi), p 3–4. In Maresca B, Kobayashi GS (ed), *Molecular biology of*
719 *pathogenic fungi, a laboratory manual*. Telos Press, New York, NY.
- 720 Hong, S. B., Go, S. J., Shin, H. D., Frisvad, J. C., and Samson, R. A. (2005). Polyphasic
721 taxonomy of *Aspergillus fumigatus* and related species. *Mycologia*.
722 doi:10.3852/mycologia.97.6.1316.
- 723 Hu, W., Sillaots, S., Lemieux, S., Davison, J., Kauffman, S., Breton, A., et al. (2007).
724 Essential gene identification and drug target prioritization in *Aspergillus fumigatus*.
725 *PLoS Pathog*. doi:10.1371/journal.ppat.0030024.
- 726 Huson, D. H., and Weber, N. (2013). Microbial community analysis using MEGAN.
727 *Methods Enzymol*. 531, 465–485.
- 728 Jiménez-Ortigosa, C., Moore, C., Denning, D. W., and Perlin, D. S. (2017). Emergence
729 of echinocandin resistance due to a point mutation in the *fks1* gene of *Aspergillus*
730 *fumigatus* in a patient with chronic pulmonary aspergillosis. *Antimicrob. Agents*
731 *Chemother*. doi:10.1128/AAC.01277-17.
- 732 Jones, P., Binns, D., Chang, H. Y., Fraser, M., Li, W., McAnulla, C., et al. (2014).
733 InterProScan 5: Genome-scale protein function classification. *Bioinformatics* 30,
734 1236–1240.
- 735 Katoh, K., and Standley, D. M. (2013). MAFFT multiple sequence alignment software
736 version 7: Improvements in performance and usability. *Mol. Biol. Evol*.
737 doi:10.1093/molbev/mst010.

- 738 Katz, M. E., Dougall, A. M., Weeks, K., and Cheetham, B. F. (2005). Multiple genetically
739 distinct groups revealed among clinical isolates identified as atypical *Aspergillus*
740 *fumigatus*. *J. Clin. Microbiol.* doi:10.1128/JCM.43.2.551-555.2005.
- 741 Keller, N. P. (2017). Heterogeneity confounds establishment of “a” model microbial strain.
742 *MBio.* doi:10.1128/mBio.00135-17.
- 743 Kjærboelling, I., Vesth, T. C., Frisvad, J. C., Nybo, J. L., Theobald, S., Kuo, A., et al. (2018).
744 Linking secondary metabolites to gene clusters through genome sequencing of six
745 diverse *Aspergillus* species. *Proc. Natl. Acad. Sci. U. S. A.*
746 doi:10.1073/pnas.1715954115.
- 747 Klopfenstein, D. V., Zhang, L., Pedersen, B. S., Ramírez, F., Vesztröcy, A. W., Naldi, A.,
748 et al. (2018). GOATOOLS: A Python library for Gene Ontology analyses. *Sci. Rep.*
749 doi:10.1038/s41598-018-28948-z.
- 750 Kowalski, C. H., Beattie, S. R., Fuller, K. K., McGurk, E. A., Tang, Y. W., Hohl, T. M., et
751 al. (2016). Heterogeneity among isolates reveals that fitness in low oxygen correlates
752 with *Aspergillus fumigatus* virulence. *MBio.* doi:10.1128/mBio.01515-16.
- 753 Kusuya, Y., Sakai, K., Kamei, K., Takahashi, H., and Yaguchi, T. (2016). Draft genome
754 sequence of the pathogenic filamentous fungus *Aspergillus lentulus* IFM 54703T.
755 *Genome Announc.* doi:10.1128/genomeA.01568-15.
- 756 Kusuya, Y., Takahashi-Nakaguchi, A., Takahashi, H., and Yaguchi, T. (2015). Draft
757 genome sequence of the pathogenic filamentous fungus *Aspergillus udagawae*
758 strain IFM 46973T. *Genome Announc.* doi:10.1128/genomeA.00834-15.

- 759 Lamoth, F. (2016). *Aspergillus fumigatus*-related species in clinical practice. *Front.*
760 *Microbiol.* doi:10.3389/fmicb.2016.00683.
- 761 Latgé, J. P., and Chamilos, G. (2020). *Aspergillus fumigatus* and aspergillosis in 2019.
762 *Clin. Microbiol. Rev.* doi:10.1128/CMR.00140-18.
- 763 Lê, S., Josse, J., and Husson, F. (2008). FactoMineR: An R package for multivariate
764 analysis. *J. Stat. Softw.* doi:10.18637/jss.v025.i01.
- 765 Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-
766 Wheeler transform. *Bioinformatics.* doi:10.1093/bioinformatics/btp324.
- 767 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The
768 Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079.
- 769 Lind, A. L., Wisecaver, J. H., Lameiras, C., Wiemann, P., Palmer, J. M., Keller, N. P., et
770 al. (2017). Drivers of genetic diversity in secondary metabolic gene clusters within a
771 fungal species. *PLoS Biol.* doi:10.1371/journal.pbio.2003583.
- 772 Liu, W., Sun, Y., Chen, W., Liu, W., Wan, Z., Bu, D., et al. (2012). The T788G mutation
773 in the *cyp51C* gene confers voriconazole resistance in *Aspergillus flavus* causing
774 aspergillosis. *Antimicrob. Agents Chemother.* doi:10.1128/AAC.05477-11.
- 775 McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytzky, A., et al.
776 (2010). The genome analysis toolkit: A MapReduce framework for analyzing next-
777 generation DNA sequencing data. *Genome Res.* doi:10.1101/gr.107524.110.

- 778 Mondon, P., De Champs, C., Donadille, A., Ambroise-Thomas, P., and Grillot, R. (1996).
779 Variation its virulence of *Aspergillus fumigatus* strains in a murine model of invasive
780 pulmonary aspergillosis. *J. Med. Microbiol.* doi:10.1099/00222615-45-3-186.
- 781 Morris, S. M., Albrecht, U., Reiner, O., Eichele, G., and Yu-Lee, L. Y. (1998). The
782 lissencephaly gene product Lis1, a protein involved in neuronal migration, interacts
783 with a nuclear movement protein, NudC. *Curr. Biol.* doi:10.1016/S0960-
784 9822(98)70232-5.
- 785 Negri, C. E., Gonçalves, S. S., Xafranski, H., Bergamasco, M. D., Aquino, V. R., Castro,
786 P. T. O., et al. (2014). Cryptic and Rare *Aspergillus* species in Brazil: Prevalence in
787 clinical samples and in Vitro susceptibility to Triazoles. *J. Clin. Microbiol.*
788 doi:10.1128/JCM.01582-14.
- 789 Nguyen, L. T., Schmidt, H. A., Von Haeseler, A., and Minh, B. Q. (2015). IQ-TREE: A fast
790 and effective stochastic algorithm for estimating maximum-likelihood phylogenies.
791 *Mol. Biol. Evol.* doi:10.1093/molbev/msu300.
- 792 Nierman, W. C., Pain, A., Anderson, M. J., Wortman, J. R., Kim, H. S., Arroyo, J., et al.
793 (2005). Genomic sequence of the pathogenic and allergenic filamentous fungus
794 *Aspergillus fumigatus*. *Nature*. doi:10.1038/nature04332.
- 795 Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht,
796 R., et al. (2016). Practice guidelines for the diagnosis and management of
797 aspergillosis: 2016 update by the infectious diseases society of America. *Clin. Infect.*
798 *Dis.* doi:10.1093/cid/ciw326.

- 799 Posch, W., Blatzer, M., Wilflingseder, D., and Lass-Flörl, C. (2018). *Aspergillus terreus*:
800 Novel lessons learned on amphotericin B resistance. *Med. Mycol.*
801 doi:10.1093/mmy/myx119.
- 802 Puértolas-Balint, F., Rossen, J. W. A., Oliveira dos Santos, C., Chlebowicz, M. M. A.,
803 Raangs, E. C., van Putten, M. L., et al. (2019). Revealing the Virulence Potential of
804 Clinical and Environmental *Aspergillus fumigatus* Isolates Using Whole-Genome
805 Sequencing. *Front. Microbiol.* doi:10.3389/fmicb.2019.01970.
- 806 Ries, L. N. A., Steenwyk, J. L., De Castro, P. A., De Lima, P. B. A., Almeida, F., De Assis,
807 L. J., et al. (2019). Nutritional heterogeneity among *aspergillus fumigatus* strains has
808 consequences for virulence in a strain- And host-dependent manner. *Front.*
809 *Microbiol.* doi:10.3389/fmicb.2019.00854.
- 810 Rivero-Menendez, O., Cuenca-Estrella, M., and Alastruey-Izquierdo, A. (2019). In vitro
811 activity of olorofim (F901318) against clinical isolates of cryptic species of *Aspergillus*
812 by EUCAST and CLSI methodologies. *J. Antimicrob. Chemother.*
813 doi:10.1093/jac/dkz078.
- 814 Robbins, N., Caplan, T., and Cowen, L. E. (2017). Molecular Evolution of Antifungal Drug
815 Resistance. *Annu. Rev. Microbiol.* doi:10.1146/annurev-micro-030117-020345.
- 816 Rokas A, Mead ME, Steenwyk JL, Oberlies NH, Goldman GH (2020) Evolving moldy
817 murderers: *Aspergillus* section *Fumigati* as a model for studying the repeated
818 evolution of fungal pathogenicity. *PLoS Pathog* 16(2): e1008315
- 819 Sharma, C., Kumar, R., Kumar, N., Masih, A., Gupta, D., and Chowdhary, A. (2018).
820 Investigation of multiple resistance mechanisms in voriconazole-resistant *aspergillus*

- 821 flavus clinical isolates from a chest hospital surveillance in Delhi, India. *Antimicrob.*
822 *Agents Chemother.* doi:10.1128/AAC.01928-17.
- 823 Simão, F. A., Waterhouse, R. M., Ioannidis, P., Kriventseva, E. V., and Zdobnov, E. M.
824 (2015). BUSCO: Assessing genome assembly and annotation completeness with
825 single-copy orthologs. *Bioinformatics.* doi:10.1093/bioinformatics/btv351.
- 826 Stanke, M., Steinkamp, R., Waack, S., and Morgenstern, B. (2004). AUGUSTUS: A web
827 server for gene finding in eukaryotes. *Nucleic Acids Res.* 32.
- 828 Steenwyk, J. L., Shen, X.-X., Lind, A. L., Goldman, G. H. & Rokas, A. A Robust
829 Phylogenomic Time Tree for Biotechnologically and Medically Important Fungi in
830 the Genera *Aspergillus* and *Penicillium*. *MBio* 10, (2019).
- 831 Sugui, J. A., Peterson, S. W., Figat, A., Hansen, B., Samson, R. A., Mellado, E., et al.
832 (2014). Genetic relatedness versus biological compatibility between *Aspergillus*
833 *fumigatus* and related species. *J. Clin. Microbiol.* doi:10.1128/JCM.01704-14.
- 834 Szalewski, D. A., Hinrichs, V. S., Zinniel, D. K., and Barletta, R. G. (2018). The
835 pathogenicity of *Aspergillus fumigatus*, drug resistance, and nanoparticle delivery.
836 *Can. J. Microbiol.* doi:10.1139/cjm-2017-0749.
- 837 Takahashi-Nakaguchi, A., Muraosa, Y., Hagiwara, D., Sakai, K., Toyotome, T.,
838 Watanabe, A., et al. (2015). Genome sequence comparison of *Aspergillus fumigatus*
839 strains isolated from patients with pulmonary aspergilloma and chronic necrotizing
840 pulmonary aspergillosis. *Med. Mycol.* doi:10.1093/mmy/myv003.
- 841 Tavaré, S. Some probabilistic and statistical problems in the analysis of DNA sequences.
842 *Lect. Math. life Sci.* 17, 57–86 (1986).

- 843 Taylor, J. W., Jacobson, D. J., Kroken, S., Kasuga, T., Geiser, D. M., Hibbett, D. S., et al.
844 (2000). Phylogenetic species recognition and species concepts in fungi. *Fungal*
845 *Genet. Biol.* doi:10.1006/fgbi.2000.1228.
- 846 Tsai, H. F., Chang, Y. C., Washburn, R. G., Wheeler, M. H., and Kwon-Chung, K. J.
847 (1998). The developmentally regulated alb1 gene of *Aspergillus fumigatus*: Its role in
848 modulation of conidial morphology and virulence. *J. Bacteriol.*
849 doi:10.1128/jb.180.12.3031-3038.1998.
- 850 Vinet, L. & Zhedanov, A. A 'missing' family of classical orthogonal polynomials. *J. Phys.*
851 *A Math. Theor.* **44**, 085201 (2011).
- 852 Walker, B. J., Abeel, T., Shea, T., Priest, M., Abouelliel, A., Sakthikumar, S., et al. (2014).
853 Pilon: An integrated tool for comprehensive microbial variant detection and genome
854 assembly improvement. *PLoS One*. doi:10.1371/journal.pone.0112963.
- 855 Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M., and Barton, G. J. (2009).
856 Jalview Version 2-A multiple sequence alignment editor and analysis workbench.
857 *Bioinformatics*. doi:10.1093/bioinformatics/btp033.
- 858 Waterhouse, R. M., Tegenfeldt, F., Li, J., Zdobnov, E. M. & Kriventseva, E. V. OrthoDB:
859 a hierarchical catalog of animal, fungal and bacterial orthologs. *Nucleic Acids Res.*
860 **41**, D358–D365 (2013).
- 861 Winnenburg, R. (2006). PHI-base: a new database for pathogen host interactions. *Nucleic*
862 *Acids Res.* doi:10.1093/nar/gkj047.
- 863 Yang, Z. Maximum likelihood phylogenetic estimation from DNA sequences with variable
864 rates over sites: Approximate methods. *J. Mol. Evol.* **39**, 306–314 (1994).

- 865 Yang, Z. Among-site rate variation and its impact on phylogenetic analyses. *Trends Ecol.*
866 *Evol.* **11**, 367–372 (1996).
- 867 Zakaria, A., Osman, M., Dabboussi, F., Rafei, R., Mallat, H., Papon, N., et al. (2020).
868 Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of
869 resistance in clinical *Aspergillus* species: A general review with a special focus on
870 the Middle Eastern and North African region. *J. Infect. Public Health.*
871 doi:10.1016/j.jiph.2019.08.007.
- 872 Zbinden, A., Imhof, A., Wilhelm, M. J., Ruschitzka, F., Wild, P., Bloemberg, G. V., et al.
873 (2012). Fatal outcome after heart transplantation caused by *Aspergillus lentulus*.
874 *Transpl. Infect. Dis.* doi:10.1111/j.1399-3062.2012.00779.x.
- 875 Zheng, B., Yan, L., Liang, W., and Yang, Q. (2019). Paralogous Cyp51s mediate the
876 differential sensitivity of *Fusarium oxysporum* to sterol demethylation inhibitors. *Pest*
877 *Manag. Sci.* doi:10.1002/ps.5127.

878 **Figure Legends**

879

880 **Figure 1.** High heterogeneity in drug susceptibility profiles among Spanish strains of three
881 closely related *Aspergillus* pathogens. **(A)** Antifungal susceptibility testing was carried out
882 using EUCAST 9.3. FactoMineR v. 2.1 PCA function was used to scale variables (drug
883 MIC/MECs) and compute Principal Components (PCs), and factoextra v.1.0.6 was used
884 to plot results. PC1 (Dim1) explains most of the variation (37.2% of the variation) and is
885 able to separate *A. fumigatus* from other two species, whereas an overlap is observed in
886 cryptic species (*A. lentulus* and *A. fumigatiaffinis*). **(B)** Antifungal susceptibility testing was
887 carried out using EUCAST 9.3. The Minimum inhibitory concentration (MIC) was obtained
888 for AMB, VCZ, PCZ and ICZ and the Minimum Effective Concentration (MEC) was
889 obtained for TRB, CPF, MCF and AND. A lower scale is shown for echinocandins (bottom
890 panel). Antifungal classes are A: Polyenes; B: Azoles; C: Allylamines; D: Echinocandins.
891 AMB: AmphotericinB; ICZ: itraconazole; VCZ: voriconazole; PCZ: posaconazole; CPF:
892 caspofungin; MCF: micafungin; AND: anidulafungin; TRB: Terbinafine.

893

894 **Figure 2.** High heterogeneity of virulence levels among Spanish strains of three closely
895 related *Aspergillus* pathogens. Cumulative survival in the model moth *Galleria mellonella*.
896 Larvae infection was carried out via inoculation of 10⁶ conidia. For inoculations, 10 larvae
897 were infected per clinical strain. Experiments were carried out with clinical strains of *A.*
898 *fumigatus* (upper), *A. lentulus* (middle), and *A. fumigatiaffinis* (lower).

899

900 **Figure 3.** Genomics of the three closely related *Aspergillus* pathogens. **(A)** Genome-
901 scale phylogeny of the section *Fumigati* species used in this study and additional species
902 with sequenced genomes. The *A. viridinutans* clade is presented as a sister clade.
903 Spanish strains sequenced in this work are colored in red (*A. fumigatus*), blue (*A. lentulus*)
904 and black (*A. fumigatiaffinis*). The newly sequenced *A. fumigatiaffinis* strains form a
905 separated group that is closely related to *A. novofumigatus*. All *A. lentulus* strains in this
906 work group together and share an ancestor with *A. lentulus* IFM54703, the only
907 sequenced strain in this species to date. The *A. fumigatus* strains sequenced in this work
908 form different internal groups in the clade with other strains in the species (e.g. strains
909 CNM-CM8714 and CNM-CM8812 group together and strains CNM-CM8686 and CNM-
910 CM8689 form another group). **(B)** *A. fumigatiaffinis* and *A. lentulus* shares the highest
911 number of common orthogroups and *A. fumigatiaffinis* displays the highest number of
912 exclusive orthogroups. OrthoFinder v.2.3.3 was used to group proteins in all clinical
913 strains into orthogroups. *In house* Perl scripts were used to recover orthogroups in each
914 species and VennDiagram in R (Chen and Boutros, 2011) was used to draw intersections.
915 We considered species-specific orthologs those that were present in at least one strain
916 of a given species, with no representative from another species. **(C)** Orthogroups shared
917 by all and “all but one” strains are the most frequent in three closely related *Aspergillus*
918 pathogens. OrthoFinder v.2.3.3 (Emms and Kelly, 2015) was used to group proteins in all
919 clinical strains into orthogroups. *A. lentulus*, *A. fumigatus* and *A. fumigatiaffinis* presented
920 9,008, 8,321, and 9,423 orthologous genes present in all strains, respectively. The five
921 largest combination of orthogroups are shown. As expected, the most frequent
922 combination of orthogroups are those in all strains but one. A high number of orthogroups

923 are shared between *A. fumigatus* CNM-CM8714 and CNM-CM8812, reflecting their close
924 phylogenetic relationship.

925

926 **Figure 4.** Changes in important genes related to antifungal susceptibility in the three
927 *Aspergillus* pathogens. **(A)** Products of genes related to antifungal resistance, *Cyp51A*
928 (azoles) and *Fks1* (echinocandins), display species- and strain-specific polymorphisms.
929 MAFFT v.7.397 (--auto mode) was used to align protein sequences. Alignments were
930 imported in Jalview v.2.10.3 (Waterhouse et al., 2009), colored in Clustal mode, and non-
931 polymorphic positions were hidden. Only the positions with changes in at least one strain
932 are shown (substitutions or insertions/deletions). Blue triangles highlight amino acid
933 changes in position 98 in *Cyp51A* and in hot spot 2 (HS2) of *Fks1*. Red triangles indicate
934 insertions/deletions. **(B)** Promoter region of the *cyp51A* gene displays strain-specific
935 mutations among Spanish strains of three closely related *Aspergillus* pathogens. A *in*
936 *house* python script was used to recover 400 bp upstream to the *cyp51A* gene and the
937 three initial codons. MAFFT v.7.397 (--auto mode) was used to align the nucleotide
938 sequences in all clinical strains. Well-known Tandem Repeat regions in antifungal-
939 resistant strains of *A. fumigatus* are shown between positions 70-140 in the alignment
940 (i.e. TR34 and TR46, observed in CNM-CM8714 and CNM-CM8057, respectively,
941 delimited by two blue arrows in upper part). Polymorphisms in cryptic species were also
942 identified, for instance, the short deletions exclusively found in the cryptic species (either
943 in *A. fumigatiaffinis* or *A. lentulus*) around positions 230-250. Red arrow and red font
944 indicates the start codon. **(C)** Phylogeny of *Cyp51* gene family (protein sequences)
945 reveals three different members (*Cyp51A*, *Cyp51B*, and the putative *Cyp51C*) in *A.*

946 *fumigatiaffinis*. A maximum-likelihood phylogeny was generated in IQ-Tree (v. 1.6.12),
947 using 1000 Ultrafast Bootstrap Approximation (UFBoot) replicates. LG+G4 model was
948 chosen as the best according to Bayesian Information Criterion (BIC). UFBoot and SH-
949 aLRT support values are shown.

950

951 **Figure 5.** Orthogroups for virulence determinants reveals variable number of paralogs
952 among the three closely related *Aspergillus* pathogens. We searched for 215 known
953 genetic determinants of virulence in *A. fumigatus* Af293 in the species of interest and
954 found they were grouped into 203 orthogroups. 146/203 were found in single copy across
955 all strains and are not shown here. The cladogram above the species reflects similarities
956 between strain presence/absence patterns. *A. fumigatus* Af293 shows a different pattern
957 compared to other strains of *A. fumigatus*, grouping with one of the *A. lentulus* strains
958 (CNM-CM8927). This may reflect the phylogenetic divergence of *A. fumigatus* strain
959 Af293 from other species members. Conidial pigment polyketide synthase *alb1*
960 (Afu2g17600) is one of the genetic determinants of virulence with highest number of
961 copies in cryptic species (n=7) when compared to *A. fumigatus* strains (n=4). Gene
962 identifiers in *A. fumigatus* Af293 are highlighted in bold.

963

964 **Tables**

965 **Table 1.** Susceptibility profile of cryptic *Aspergillus* species isolated in the Mycology

966 Reference Laboratory of Spain.

Species	Strain Identifier	MIC (mg/L)				MEC (mg/L)			
		AMB	ICZ	VCZ	PCZ	TRB	CPF	MCF	AND
<i>Aspergillus lentulus</i>	CNM-CM6069	8	0.5	2	0.12	0.5	1	0.015	0.015
	CNM-CM6936	16	0.5	4	0.25	2	2	0.03	0.03
	CNM-CM7927	8	0.5	2	0.12	0.5	0.06	0.015	0.007
	CNM-CM8060	0.12	0.25	1	0.12	0.5	2	0.06	0.03
	CNM-CM8694	2	0.12	0.25	0.06	32	0.03	0.03	MD
	CNM-CM8927	16	2	1	0.25	2	0.25	0.015	0.015
<i>Aspergillus fumigatiaffinis</i>	CNM-CM5878	1	0.25	0.5	0.06	0.25	1	0.03	0.015
	CNM-CM6457	16	16	2	0.25	1	0.25	0.03	0.007
	CNM-CM6805	16	0.25	2	0.12	0.25	0.5	0.03	0.03
	CNM-CM8980	16	0.5	2	0.5	0.5	0.12	0.007	0.015
<i>Aspergillus fumigatus</i>	CNM-CM8057	0.25	>8	>8	1	16	0.5	0.06	0.12
	CNM-CM8714	0.25	>8	4	1	4	0.25	0.007	0.03

	CNM-CM8812	0.25	0.25	0.5	0.12	1	0.25	0.03	0.03
	CNM-CM8686	0.5	0.25	0.25	0.12	2	0.25	0.015	0.015
	CNM-CM8689	1	1	8	0.25	16	0.5	0.125	0.03
	Af293	0.5	1	1	0.125	2	0.125	0.007	0.007
One-way ANOVA (between species)	P-value	0.025*	0.435	0.209	0.171	0.492	0.364	0.462	0.242
Tukey multiple comparisons of means	<i>Aspergillus fumigatus</i> - <i>Aspergillus fumigatiaffinis</i>	0.0245507*	-	-	-	-	-	-	-
	<i>Aspergillus lentulus</i> - <i>Aspergillus fumigatiaffinis</i>	0.5595621	-	-	-	-	-	-	-
	<i>Aspergillus lentulus</i> - <i>Aspergillus fumigatus</i>	0.0982057	-	-	-	-	-	-	-



967

968

969 **Table 2.** Single-nucleotide polymorphisms and insertions / deletions in *cyp51* family and
 970 *fks1* genes in each species individually.

Species	Polymorphism type	Gene	High impact variant	Low impact variant	Moderate impact variant	Modifier impact variant
<i>A. fumigatus</i>	INDELs	<i>cyp51A</i>	0	0	0	6
<i>A. fumigatus</i>	SNPs	<i>cyp51A</i>	0	0	5	23
<i>A. lentulus</i>	INDELs	<i>cyp51A</i>	0	0	0	10
<i>A. lentulus</i>	SNPs	<i>cyp51A</i>	0	8	3	92
<i>A. fumigatus</i>	INDELs	<i>cyp51B</i>	0	0	0	1
<i>A. fumigatus</i>	SNPs	<i>cyp51B</i>	0	1	1	7
<i>A. lentulus</i>	INDELs	<i>cyp51B</i>	0	0	0	1
<i>A. lentulus</i>	SNPs	<i>cyp51B</i>	0	0	0	2
<i>A. fumigatiaffinis</i>	INDELs	<i>cyp51C</i>	0	0	0	28
<i>A. fumigatiaffinis</i>	SNPs	<i>cyp51C</i>	0	10	1	157
<i>A. fumigatiaffinis</i>	INDELs	<i>fks1</i>	0	0	0	45
<i>A. fumigatiaffinis</i>	SNPs	<i>fks1</i>	0	23	5	143
<i>A. fumigatus</i>	INDELs	<i>fks1</i>	0	0	0	3
<i>A. fumigatus</i>	SNPs	<i>fks1</i>	0	4	0	10
<i>A. lentulus</i>	INDELs	<i>fks1</i>	4	0	0	50
<i>A. lentulus</i>	SNPs	<i>fks1</i>	0	43	5	218

971



A. fumigatus





Figure 2

Strain

- Af293
- CNM-CM8057
- CNM-CM8686
- CNM-CM8689
- CNM-CM8714
- CNM-CM8812
- PBS


A. lentulus



Strain

- CNM-CM6069
- CNM-CM6936
- CNM-CM7927
- CNM-CM8060
- CNM-CM8694
- CNM-CM8927
- PBS

A. fumigatiaffinis



Strain

- CNM-CM5878
- CNM-CM6457
- CNM-CM6805
- CNM-CM8980
- PBS


A

Figure 3




B

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.28.970384>; this version posted February 28, 2020. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under aCC-BY-NC 4.0 International license.



C








Figure 4

Figure 5

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.28.070384>; this version posted February 28, 2020. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under aCC-BY-NC 4.0 International license.

